OUR IMPACT.
We don’t just support research. We transform how it’s done.
Impact in Action.
675+
Research grants funded
Backing the most impactful science—free from bias or boundaries—to accelerate progress in ALS research.
$80.4M
Invested in ALS research
Strategic, mission-driven funding focused on accelerating the path to breakthroughs with one goal in mind: a world where Everyone Lives.
56%
Of our funded consortia have led to drug discovery programs
Our collaborative model is driving real progress—more than half of our consortia have advanced into the drug discovery pipeline.
10
Clinical trials have emerged from our funded work
From lab to life—our funded work has directly contributed to clinical trials aiming to bring new treatments to those living with ALS.
1650+
Academic and industry users utilizing our Research Cores
Researchers around the world rely on our no-strings-attached Research Cores to accelerate innovation and expand scientific understanding.
14
Active global research sites enrolling participants
We’ve created a truly inclusive research ecosystem by supporting sites across the globe, including historically underrepresented communities.
Reimagining Research. Redefining What’s Possible.
At Target ALS, we didn’t just join the fight—we changed the rules.
Our Innovation Ecosystem unites academia, pharma and biotech, venture capital, government, other ALS nonprofits, and the ALS community, in radical collaboration, breaking down traditional silos to fast-track breakthroughs. This game-changing model is transforming how ALS research gets done—and it’s getting noticed.
Target ALS Highlighted in New Case Study Released by Harvard Kennedy School Focused on Innovative Model for Collaborative Medical Research
“The Harvard Kennedy School case study captures the urgency, collaboration, and strategic thinking that have driven Target ALS. This is a blueprint not just for ALS, but for solving any seemingly intractable problem.”
– Dan Doctoroff, Target ALS Founder
Unlocking Discovery. No Strings Attached.
At Target ALS, we believe that access drives innovation. That’s why we offer the global research community unrestricted, no-strings-attached access to some of the most comprehensive ALS biosample and tool collections available—resources that would otherwise be out of reach for many labs.
No other nonprofit in ALS does this.
And it’s making an undeniable impact: our Research Cores are used by 1650+ researchers around the world to push the boundaries of what’s possible.
“Without Target ALS’s access to these stem cell lines, the process of creating such models would be significantly more costly and time-consuming… these stem cell banks are sometimes not publicly available, so it’s been instrumental in advancing our research.”
Dr. Kathryn H. Morelli, Ph.D.
Assistant Professor at University of Vermont
Dept. of Neurological Sciences
Data Without Barriers: Empowering Global ALS Research
The Target ALS Data Engine is a first-of-its-kind platform giving researchers around the world free access to powerful ALS data—all in one place. Built in partnership with DNAstack and Verily, it includes easy-to-use tools to search, explore, and analyze multi-omic data linked to real biosamples.
By removing paywalls, red tape, and intellectual property restrictions, we’re speeding up the path to new discoveries.
No barriers. No strings attached. Just science, accelerated.
“The way I’ve used the resource thus far has really helped me with hypothesis generation… It’s a really big deal, because that stuff just takes so much time. Target ALS runs a very tight ship, so I have trusted this resource implicitly.”
Cooper Penner
MD-PhD Candidate, University of Pennsylvania
Department of Neuroscience
The Road Ahead
Every discovery we fuel. Every dataset we open. Every voice we amplify. It all brings us one step closer to a world where Everyone Lives.
At Target ALS, we don’t wait for breakthroughs — we build the infrastructure, forge the partnerships, and fund the bold ideas that make them possible.
But we can’t do it alone.
Join us. Partner with us. Stand with the ALS community. Because together, we’re not just accelerating research — we’re rewriting the future.
